Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a single MRI-Guided biopsy replace the standard battery?

NCT ID NCT05612204

Diagnosis Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study explores whether using only MRI-targeted prostate biopsies—instead of combining them with standard systematic biopsies—can provide enough information for doctors to decide on treatment. Men aged 50 to 75 with suspected prostate cancer and a single suspicious lesion on MRI will participate. The goal is to see if the treatment plan based on targeted biopsies alone matches the one made with both biopsy types, potentially reducing unnecessary procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Targeted prostate biopsy under MRI guidance
What this could lead to
If MRI-targeted biopsies alone are enough, men might avoid the discomfort and risk of extra systematic biopsies, making diagnosis less invasive.
What could go wrong
This is a small exploratory study, and MRI-targeted biopsies might miss some cancers that systematic biopsies would catch, so treatment decisions could differ.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

51 people

The number who actually took part.

Started

Nov 2022

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 75 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient, male, aged between ≥ 50 and ≤ 75 years old * Patient with no history of prostate biopsy * Patient with a PSA greater than 4 and/or a pathological digital rectal examination * Patient having an MRI of interpretable quality carried out within the HPA * Patient with a single lesion with a PI-RADS score ≥ 3 * Affiliated patient or beneficiary of a social security scheme * French-speaking patient who signed an informed consent Exclusion Criteria: * Patient with a contraindication to MRI * Patient with multiple targets * Patient with lesions with PI-RADS score 1 and 2 * Patient on long-term anticoagulants and unable to stop it * Patient already included in another study * Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision * Patient hospitalized without consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • HPA

    Antony, 92160, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.